Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung Disease: a Pilot Study
Condition(s):Interstitial Lung Disease; Myopathy, InflammatoryLast Updated:April 19, 2022Recruiting
Hide Studies Not Open or Pending
Condition(s):Interstitial Lung Disease; Myopathy, InflammatoryLast Updated:April 19, 2022Recruiting
Condition(s):Bronchiolitis Obliterans Syndrome (BOS); Bronchiolitis Obliterans (BO)Last Updated:February 1, 2024Recruiting
Condition(s):Idiopathic Pulmonary FibrosisLast Updated:June 13, 2018Completed
Condition(s):Renal Cell Carcinoma; Colorectal Adenocarcinoma; Non-squamous Non-small Cell Lung Cancer; Platinum-refractory Ovarian Carcinoma; Cervical CarcinomaLast Updated:July 10, 2018Completed
Condition(s):Breast CancerLast Updated:July 17, 2019Terminated
Condition(s):Myositis Associated Interstitial Lund Disease (MA-ILD)Last Updated:September 7, 2023Recruiting
Condition(s):Pulmonary FibrosisLast Updated:January 2, 2024Withdrawn
Condition(s):Recurrent or Metastatic Salivary Gland Cancer of the Head and NeckLast Updated:November 20, 2015Unknown status
Condition(s):SARS-Cov-2 Induced Pulmonary FibrosisLast Updated:May 3, 2022Recruiting
Condition(s):Lung Diseases, InterstitialLast Updated:April 25, 2023Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.